Over the past decade, our knowledge of the clinical diagnosis and management of
thalassemia has progressed extensively. In recent years, the most critical change in clinical …

Iron-Chelating Therapy for Transfusional Iron Overload | NEJM Skip to main content NEJM
Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to become a …

This aim of this statement is to report an expert consensus on the diagnosis and treatment of
cardiac dysfunction in β-thalassemia major (TM). This consensus statement does not cover …

Despite recent advances in understanding the pathophysiologic mechanisms behind the
thalassemia intermedia (TI) phenotype, data on the effects of treatment are deficient. To …

Inherited haemoglobinopathies are the most common monogenic diseases, with millions of
carriers and patients worldwide. At present, we know several hundred disease-causing …

Patients with β-thalassemia major (TM) and other refractory anemias requiring regular blood
transfusions accumulate iron that damages the liver, endocrine system, and most importantly …

Recent molecular studies of fetal hemoglobin (HbF) regulation have reinvigorated the field
and shown promise for the development of clinical HbF inducers to be used in patients with …

Abstract β-thalassemia major causes ineffective erythropoiesis and chronic anemia and is
associated with iron overload due to both transfused iron and increased iron absorption, the …

Iron overload is a pathological condition resulting from a congenital impairment of its
regulation, increased intestinal iron absorption secondary to bone marrow erythroid …

Pancreatic iron overload and diabetes mellitus (DM) are common in thalassemia major
patients. However, the relationship between iron stores and glucose disturbances is not well …